In another trial involving patients with HER2 low metastatic BC, Modi et al. also showed that trastuzumab deruxtecan significantly prolonged PFS and OS compared to the other chemotherapy regimens (Modi et al., 2020b; Modi et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.